New research findings from the world’s largest study on language emergence have revealed that one in four late talking toddlers continue to have language problems by age 7.The LOOKING at Language project has analysed the speech development of 1766 children in Western Australia from infancy to seven years of age, with particular focus on environmental, neuro-developmental and genetic risk factors. It is the first study to look at predictors of late language.

OSU’s Technology Business Assessment Group will fund four faculty research projects for spring 2008. The group identified these one-year projects from a number of excellent proposals submitted in response to a solicitation earlier this spring. Funding for the program is administered by the OSU Office of Intellectual Property Management, and is generated by royalties from OSU-licensed technologies. These funded projects show a significant probability of having commercial success.

The International Diabetes Federation (IDF) BRIDGES translational research grant program will fund STOP Diabetes, a project to be implemented and studied in Australia. The STOP project is designed to reduce the risk for type 2 diabetes in women by encouraging healthy behaviours.

The American Society of Clinical Oncology Cancer Foundation has selected Yu-Ning Wong, M.D., M.S.C.E., of Fox Chase Cancer Center, as one of 13 clinicians to receive a 2008 Career Development Award. Career Development Awards are presented to physicians in their second, third or fourth year as full-time faculty members in an academic setting. This award marks the third time ASCO has honored Wong’s accomplishments since she began her professional career in oncology in 2002.

A study led by Dr. Ann F. Jacobson, associate professor in Kent State’s College of Nursing, unveils the reasons why people may initially choose to postpone but ultimately undergo total knee replacement surgery and emphasizes the need for better patient education before and after the procedure.

Maintaining bone density could be a key to decreasing the spread of cancer in women with locally advanced breast cancer, according to research at Washington University School of Medicine in St. Louis.Bones are common sites for the spread, or metastasis, of breast cancer. Scientists here found that women treated for stage II/III breast cancer who also received a bone strengthening drug were less likely to have breast tumor cells growing in their bones after three months.

New research findings from a top clinical investigator at The Cancer Institute of New Jersey (CINJ) indicate the potential for more targeted treatment of ovarian cancer, which is expected to claim more than 15,000 lives nationwide this year, with 480 in New Jersey.

Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced that Nexavar(R) (sorafenib) tablets significantly improved overall survival by 47.3 percent (HR=0.68; p-value=0.014) in patients in the Asia-Pacific region with advanced hepatocellular carcinoma (HCC), or primary liver cancer versus those receiving placebo. Nexavar also significantly improved time to progression in these patients by 74 percent (HR=0.57; P=0.001).

Results of a new analysis of the Treating to New Targets (TNT) study show that intensive low-density lipoprotein (LDL) cholesterol-lowering in patients with stable coronary heart disease (CHD) whose systolic blood pressure was less than 140 mmHg reduced the risk of major cardiovascular events, including heart attack, stroke and resuscitated cardiac arrest, by 42 percent compared with less intensive LDL lowering and uncontrolled blood pressure of 140 mmHg or higher.Led by John B.

Boston Scientific Corporation (NYSE: BSX) announced U.S. Food and Drug Administration (FDA) approval of its ACUITY(R) Spiral left ventricular lead for use with cardiac resynchronization therapy defibrillators (CRT-D) and cardiac resynchronization therapy pacemakers (CRT-P), both of which treat heart failure. The ACUITY Spiral lead is the Company’s fifth generation left ventricular lead and second in the ACUITY family of left ventricular leads.